Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.

Zhao, Y J; Wee, H L; Au, W L; Seah, S H; Luo, N; Li, S C; Tan, L C S

Zhao, Y J; Wee, H L; Au, W L; Seah, S H; Luo, N; Li, S C; Tan, L C S.

Affiliation

Zhao YJ; Department of Pharmacy, National University of Singapore, Republic of Singapore.

Parkinsonism Relat Disord ; 17(3): 194-7, 2011 Mar.

Article in En | MEDLINE | ID: mdl-21159539

Subject(s)

Disease Progression; Neuroprotective Agents/therapeutic use; Parkinson Disease/drug therapy; Parkinson Disease/physiopathology; Psychiatric Status Rating Scales; Selegiline/therapeutic use; Aged; Disability Evaluation; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinson Disease/ethnology; Proportional Hazards Models

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Psychiatric Status Rating Scales / Selegiline / Neuroprotective Agents / Disease Progression Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2011 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google